Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4947 - Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Pancreatic Adenocarcinoma


Louise Rasmussen


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


L.S. Rasmussen1, M. Yilmaz1, U.G. Falkmer1, L.Ø. Poulsen1, S.E. Bojesen2, B. Vittrup Jensen3, A.Z. Johansen3, I.M. Chen3, C.P. Hansen4, J.P. Hasselby5, P. Pfeiffer6, J.K. Bjerregaard6, S.E. Nielsen3, F.Z. Andersen7, N.H. Holländer8, M. Bøgsted9, J.S. Johansen3

Author affiliations

  • 1 Department Of Oncology, Aalborg University hospital, 9000 - Aalborg/DK
  • 2 Department Of Clinical Biochemistry, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 3 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 4 Department Of Surgery, Rigshospitalet, University of Copenhagen, 2100 - Copenhagen/DK
  • 5 Department Of Pathology, Rigshospitalet, University of Copenhagen, 2100 - Copenhagen/DK
  • 6 Department Of Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 7 Department Of Oncology, Zealand University Hospital, Hillerød, 3400 - Hillerød/DK
  • 8 Departemnt Of Oncology, Zealand University Hospital, Næstved, 4700 - Næstved/DK
  • 9 Department Of Haematology, Aalborg University Hospital, 9000 - Aalborg/DK


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4947


25-hydroxyvitamin D and active analogues have shown to inhibit growth of pancreatic cancer (PC) cell lines. However, studies describing the relationship between serum levels of vitamin D and survival in PC patients have shown conflicting results. The aim of the study was to evaluate the association between pre-treatment 25-hydroxyvitamin D levels and survival in Danish patients with PC.


In the prospective BIOPAC study (NCT03311776), the pre-treatment serum 25-hydroxyvitamin D (S-25(OH)D) concentrations were determined in 1233 patients with PC included from July 2008 to December 2018, using the DiaSorin Liaison 25-hydroxyvitamin D TOTAL assay. Age (median 67 years), gender (male/female: 675/558), BMI (<18.5/18.5-25/>25/unknown: 96/663/356/118), Performance status (PS) (0/1/2 + 3/unknown: 422/498/135/177) and stage (I+II/III+IV/unknown: 408/758/67) were retrieved. Survival was estimated in three S-25(OH)D groups as: insufficient <25 nmol/L, relatively insufficient 25-50 nmol/L and sufficient >50 nmol/L. For survival analysis, Kaplan-Meier plots, log-rank tests and the Cox regression model were used.




S-25(OH)D levelsPt, No.mOS, months95%CIPt, No.mOS, months95%CI
Relatively insufficient15622.918.3-27.82756.35.3-7.2

Abbreviations: Pt, No.: Patient number, mOS: median overall survival, CI: Confidence interval. Overall survival between the three S-25(OH)D groups in stages I and II, log rank p = 0.03, as well as in stages III and IV, log rank p = 0.02, were significantly different. In the multivariate Cox regression analysis, patients with sufficient S-25(OH)D levels had longer survival than those with insufficient levels (HR = 0.77, 95% CI 0.62-0.96; p = 0.02). PS 0 vs. 1 and vs. 2 + 3 (p < 0.01) and tumour stage I+II vs. III+IV (p < 0.01) were also associated with longer survival whereas age, gender and BMI were not.


Patients with PC and sufficient pre-treatment serum 25-hydroxyvitamin D levels had significantly longer OS than those with insufficient levels across all stages.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Julia Sidenius Johansen.


Axel Muusfeldt’s Foundation.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.